Most men (73%) were receiving GnRH agonist treatment (triptorelin, leuprorelin, or goserelin) in the context of a new diagnosis of prostate cancer; 66% had comorbidities (Table 1). The gene discussed is GNRH1; the disease is prostate carcinoma.